Abliva AB Interim Report January – September 2021
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Press releases
Abliva AB Interim Report January – June 2021
Second quarter summary
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 74,065,306, as a result of a directed new issue of shares resolved by the Board of ...
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...
Abliva AB Interim Report January – March 2021
First quarter summary
Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive ...
Abliva publishes prospectus and new information contained in the prospectus
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, tod ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 32,601,360 as a result of a directed new issue of shares resolved by the Board of ...
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...
Abliva AB publishes 2020 Annual report
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.